Results 1 to 10 of about 111,723 (116)
Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells [PDF]
Frontiers in PharmacologyMultiple myeloma is an incurable cancer that originates from antibody-producing plasma cells. It is characterized by an intrinsic ability to produce large amounts of immunoglobulin-like proteins.
Marta Pelon +3 more
doaj +2 more sources
Early recovery of proteasome activity in cells pulse-treated with proteasome inhibitors is independent of DDI2 [PDF]
eLifeRapid recovery of proteasome activity may contribute to intrinsic and acquired resistance to FDA-approved proteasome inhibitors. Previous studies have demonstrated that the expression of proteasome genes in cells treated with sub-lethal concentrations of
Ibtisam Ibtisam, Alexei F Kisselev
doaj +2 more sources
Protocol for analysis of intracellular conversion of artezomib molecules into new proteasome inhibitors in Plasmodium falciparum parasites [PDF]
STAR ProtocolsSummary: Artezomibs (ATZs), dual-pharmacophore molecules comprising of artemisinin and a parasite proteasome inhibitor, hijack parasite ubiquitin proteasome system to transform into new proteasome inhibitors following the activation of artemisinin by ...
Wenhu Zhan +3 more
doaj +2 more sources
The Role of Proteasome Inhibitors in Treating Acute Lymphoblastic Leukaemia
Frontiers in Oncology, 2021 Acute lymphoblastic leukaemia (ALL) is an aggressive haematolymphoid malignancy. The prognosis of ALL is excellent in paediatric population, however the outcome of relapse/refractory disease is dismal.
Chun-fung Sin, Pui-hei Marcus Man
doaj +1 more source
Site-Specific Proteasome Inhibitors
Biomolecules, 2021 Proteasome is a multi-subunit protein degradation machine, which plays a key role in the maintenance of protein homeostasis and, through degradation of regulatory proteins, in the regulation of numerous cell functions. Proteasome inhibitors are essential
Alexei F. Kisselev
doaj +1 more source
Proteasome Inhibitors: Harnessing Proteostasis to Combat Disease
Molecules, 2020 The proteasome is the central component of the main cellular protein degradation pathway. During the past four decades, the critical function of the proteasome in numerous physiological processes has been revealed, and proteasome activity has been linked
David J. Sherman, Jing Li
doaj +1 more source
Biomolecules, 2020 Currently, proteasome inhibitors bortezomib, carfilzomib, and ixazomib are successfully used in clinics to treat multiple myeloma. However, these agents show limited efficacy against solid tumors. Identification of drugs that can potentiate the action of
Janakiram R. Vangala +2 more
doaj +1 more source
Microbial proteasomes as drug targets.
PLoS Pathogens, 2021 Proteasomes are compartmentalized, ATP-dependent, N-terminal nucleophile hydrolases that play essentials roles in intracellular protein turnover. They are present in all 3 kingdoms.
Hao Zhang, Gang Lin
doaj +3 more sources
Postnatal proteasome inhibition induces neurodegeneration and cognitive deficiencies in adult mice: a new model of neurodevelopment syndrome. [PDF]
PLoS ONE, 2011 Defects in the ubiquitin-proteasome system have been related to aging and the development of neurodegenerative disease, although the effects of deficient proteasome activity during early postnatal development are poorly understood.
Rocío Romero-Granados +3 more
doaj +1 more source
Molecules, 2022 Proteasome inhibitors have shown relevant clinical activity in several hematological malignancies, namely in multiple myeloma and mantle cell lymphoma, improving patient outcomes such as survival and quality of life, when compared with other therapies ...
Carlota Leonardo-Sousa +7 more
doaj +1 more source